Spinoff

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.

Baxter to split in 2015

Baxter to split in 2015

By

The company, which expects a 9% to 10% sales jump in 2014, says it will split into two independent companies by the middle of next year.

Pfizer's Q4 fails to wow, but palbo' news may

Pfizer's Q4 fails to wow, but palbo' news may

By

The company said it may use Phase II data of a breast cancer drug for FDA review, part of an earnings presentation that also included its perspective on what a pre-2017 breakup would take.

Xeljanz line extension could lift drug's profile

Xeljanz line extension could lift drug's profile

By

An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.

Analyst gives Merck tough love

By

Analyst Seamus Fernandez writes that Merck needs to undergo a deep overhaul, continuing the summer narrative that has enveloped Pfizer and Novartis.

Pfizer adds more clarity to break-up plans

By

The company said Monday it was putting up walls among its businesses and will begin financial reports for each of them starting in January. The key: each has its own emerging markets business unit.

Business briefs: Onyx, Pfizer, Covidien

Onyx says no to Amgen bid, yes to other options; Pfizer/BMS may be able to expand Eliquis appeal; Covidien officially divides into two.

J&J expands pipeline in prostate cancer

By

The pharmaceutical behemoth is betting at least $650 million on the Aragon Pharmaceuticals Ph. II drug.

Business briefs: Pfizer, Novartis, Boehringer Ingelheim, Elsevier

Pfizer seeks full Zoetis split, Novartis gets another NICE Lucentis indication, BI tussles with the FDA and Elsevier names a Cleveland Clinic doc EIC

Between the lines, Read offers investors a split preview

Between the lines, Read offers investors a split preview

By

The Pfizer chief told investors that the company will provide "transparency" on its new and established products businesses, with a view toward a possible Abbott-esque spinoff down the road

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.